Altimmune (ALT) Assets Average (2011 - 2026)

Altimmune (ALT) has 16 years of Assets Average data on file, last reported at $307.8 million in Q1 2026.

• Assets Average for Q1 2026 came in at $307.8 million, up 107.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.8 million (up 107.56% YoY), and the FY2025 annual result was $209.6 million, up 19.8% from the prior year.
• Assets Average grew to $307.8 million in Q1 2026 per ALT's latest filing, from $249.2 million in the prior quarter.
• Over five years, Assets Average peaked at $307.8 million in Q1 2026 and troughed at $143.6 million in Q4 2024.
• A 5-year average of $198.1 million and a median of $197.0 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2025 and 2026: Assets Average fell 25.67% in 2025, then soared 107.56% in 2026.
• A 5-year view of Assets Average shows it stood at $216.1 million in 2022, then slipped by 12.72% to $188.6 million in 2023, then retreated by 23.87% to $143.6 million in 2024, then surged by 73.55% to $249.2 million in 2025, then rose by 23.51% to $307.8 million in 2026.
• Business Quant data shows ALT's Assets Average at $307.8 million in Q1 2026, $249.2 million in Q4 2025, and $204.4 million in Q3 2025.